Recombinant Mouse BTLA/CD272 Protein (Fc Tag)(Active) | PKSM040375

(No reviews yet) Write a Review
SKU:
575-PKSM040375
Weight:
1.00 KGS
€998.00
Frequently bought together:

Description

Recombinant Mouse BTLA/CD272 Protein (Fc Tag)(Active) | PKSM040375 | Gentaur US, UK & Europe Disrtribition

Synonyms: A630002H24

Active Protein: Active protein

Activity: A DNA sequence encoding the mouse BTLA (Q7TSA3)(Met1-Gly176) was expressed, fused with the Fc region of human IgG1 at the C-terminus.

Protein Construction: A DNA sequence encoding the mouse BTLA (Q7TSA3)(Met1-Gly176) was expressed, fused with the Fc region of human IgG1 at the C-terminus.

Fusion Tag: C-Fc

Species: Mouse

Expressed Host: HEK293 Cells

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 90 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Molecular Mass: 437 kDa

Formulation: Lyophilized from sterile PBS, pH 7.4

Reconstitution: Please refer to the printed manual for detailed information.

Background: BTLA is a inhibitory molecule which belongs to the Ig superfamily. It down-modulates immune responses. As such, reagents that regulate the binding of BTLA to its ligand or alter BTLA signaling have significant therapeutic promise. BTLA is crucial to understand the mechanism(s) of action of these antibodies before attempting clinical applications. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1).Immune CheckpointImmune Checkpoint Targets   Co-inhibitory Immune Checkpoint Targets Immunotherapy   Cancer Immunotherapy   Targeted Therapy

Research Area: N/A

View AllClose